These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 15148545

  • 1. Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.
    Cardiovasc J S Afr; 2004; 15(2):91-2. PubMed ID: 15148545
    [No Abstract] [Full Text] [Related]

  • 2. [Prospects for pharmacological effects on renin-angiotensin and sympathetic nervous systems in patients with arterial hypertension].
    Chikhladze NM.
    Ter Arkh; 2000; 72(12):67-9. PubMed ID: 11201840
    [No Abstract] [Full Text] [Related]

  • 3. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
    Hollenberg NK.
    Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
    Blankestijn PJ, Rupp H.
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
    [Abstract] [Full Text] [Related]

  • 8. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A, Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Eprosartan.
    McClellan KJ, Balfour JA.
    Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
    Voors AA, van de Wal RM, Hartog JW, Vijn RG, Hummel YM, Plokker TW, van Veldhuisen DJ, Jaarsma W.
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
    Ambrosioni E, Bombelli M, Cerasola G, Cipollone F, Ferri C, Grazioli I, Leprotti C, Mancia G, Melzi G, Mugellini A, Mulè G, Palasciano G, Salvetti A, Trimarco B.
    Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
    Shusterman NH.
    Am Heart J; 1999 Sep; 138(3 Pt 2):238-45. PubMed ID: 10467219
    [Abstract] [Full Text] [Related]

  • 18. Effects of eprosartan on target organ protection.
    de la Sierra A.
    Vasc Health Risk Manag; 2006 Sep; 2(1):79-85. PubMed ID: 17319472
    [Abstract] [Full Text] [Related]

  • 19. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
    Xu FY, Yang B, Shi D, Li H, Zou Z, Shi XY.
    Eur J Clin Pharmacol; 2012 Feb; 68(2):195-205. PubMed ID: 21881888
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.